References

1. "Food & Drug Administration, Generic Drugs: Questions and Answers". Food and Drug Administration. January 12, 2010.
2. Code of Federal Regulations Title 21, 21CFR320, Procedures for Determining the Bioavailability or Bioequivalence of Drug Products**,** Volume 5, April 1, 2011.
3. Shah V (2007), The history of bioanalytical method validation and regulation: evolution of a guidance document on bioanalytical methods validation, AAPS J., 9 (1): 43-47.
4. SOP 12: Validation of bioanalytical Methods (2003), Onkologie, 26 (6): 52-55.
5. Carr G, Walich J (1990), A practical approach to method validation in pharmaceutical analysis, J Pharm Biomed Ana, 8(12): 613-18.
6. Available at http://www.scribd.com/doc/3848359/Analytical-Method-Validation-and Instrument- Performance-Verification.
7. Viswanathan C, Bansal S, et al, February 9 (2007), Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays, The AAPS Journal; 9 (1) Article 4, E30-E31.
8. Bansal S and Destefano A, March 30 (2007), Key elements of bioanalytical method validation for small molecules, The Aaps Journal; 9 (1) Article 11, E109-E114.
9. Zimmer D (2003), Introduction to quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS), Chromatographia, 57(1): 102-108.
10. Niessena W, Tinkeb A (1995), Liquid chromatography-mass spectrometry General principles and instrumentation, J Chrom, 703(1, supple 2): 37-57.
11. Food and Drug Administration. FDA. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2001 May.
12. Khorsravan R, Grabowski B, Wu J, Joseph Ridge N, Vernille L (2005), Effect of food or antacid on febuxostat pharmacokinetics and pharmacodynamics in healthy subjects, Clinical Pharmacology & Therapeutics, 77: P03-P03.
13. Khorsravan R, Erdman K, Vernillet L, Wu J, Joseph Ridge N, Umeda S, Mulford D (2005), Effect of febuxostat on pharmacokinetics of despiramine, a CYP2D6 substrate , in healthy subjects, Clinical Pharmacology & Therapeutics, 77: P03-P03.

14. Khorsravan R, Kukulka M, Wu J, Joseph Ridge N, Vernillet L (2005), Effects of age and gender on febuxostat pharmacokinetics, pharmacodynamics, and safety in healthy subjects, Clinical Pharmacology & Therapeutics, 77: P03-P03.
15. Khorsravan R, Grabowski B, Wu J, Joseph-Ridge N, Vernillet L (2006), Pharmacokinetics, pharmacodynamics ans safety of febuxostat, a novel Non-purine selective inhibitor of xanthine oxidase, in a dose Escalation study in healthy subjects, Clin Pharmacokinet, 45: 821-841.
16. Khorsravan R, Kukulka M, Wu J, Joseph-Ridge N, Vernillet L (2008), The effect of age and gender on pharmacokinetics, pharmacodynamics and safety of febuxostat, a novel Non-purine selective inhibitor of xanthine oxidase, Journal of Clinical Pharmacology, 48: 1014-1024.
17. Robinson P, Jones M, Maddock J, Rees L (1991), Simultaneous determination of clebopride and a major metabolite N-desbenzylclebopride in plasma by capillary gas chromatography-negative-ion chemical ionization mass spectrometry, Journal of Chromatography B, 564: 147-161.
18. Thangabalan B, Elphine Prabhakar A, Kalaichelvi R, Vijyaraj Kumar P (2009), UV spectrophotometric method for determination of clebopride in pure and in pharmaceutical formulation, Rasayan Jouranl Chem, 2: 712-715.
19. Niggebrugge A, Lachance D, Grandmaison C, Levesque D (2002), Determination of Cisapride and noncisapride in human urine by API 3000 LC/MS, American association of pharmaceutical scientist journal.
20. Robinson P, Jones M, Maddock J (1988), Determination of clebopride in plasma by capillary gas chromatography-negative-ion chemical ionization mass spectrometry, Journal of Chromatography; 66: 153-163.
21. Ferreiros N, Dresen S, Alonso S, Weinmann W (2007), Validated quantitation of angiotensin II receptor antagonists in human plasma by liquid-chromatography-tandem mass spectrometry using minimum sample clean-up and investigation of ion suppression. Ther Drug Monit ; 29: 824-834.
22. Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S (1996), Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/ electrospray tandem mass spectrometry following chemical derivatization. J Mas. Spectrom; 31: 873-878.

23. Nevin E (2003), Simultaneous analysis of candesartan cilexetil and hydrochlorothiazide in human plasma and dosage forms using HPLC with a photo diode array detector. J Liq Chro Rel Technol; 26: 2581-2591.
24. Gonzalez L, Lopez J, Alonso R, Jiménez R (2002), Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chrom; 949: 49-60.
25. Subba R , Radhakrishnanand R, Suryanarayana M, Himabindu V (2007), A stability-indicating LC method for Candesartan Cilexetil. Chromatographia; 66: 7-8.
26. Xiaoshan Z (2002), Determination of the content of candesartan cilexetil by HPLC. J china Pharm;11.
27. Xiu-H W, Yu-kai H, Xinhua Z, Luo J (2004), HPLC determination of candesartan cilexetil and its related substances. central south pharma; 02.
28. Peng P (2004), Chen Z. RP dissolution of Candesartan Cilexetil tablets and capsules. China's pharmaceutical industry magazine; 10.
29. Erk N (2003), Application of first derivative UV-spectrophotometry and ratio derivative spectrophotometry for the simultaneous determination of candesartan cilexetil and hydrochlorothiazide. Pharmazie; 58: 796-800.
30. Mohammed J, Zheng O, Yuan-Qing X (2010), Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography, Biomedical Chromatography, Volume 24, Issue 1, 2–19.
31. Sharma D, Mittal R, Gupta A, Singh K, Nair A, (2010), Quantitative Bioanalysis by LC-MS/MS: A Review; journal of pharmaceutical and biomedical sciences, 7 (01),1-9.
32. Wal P, Kumar B, Bhandari A, Rai AK, Wal A (2010), Bioanalytical method development-Determination of drugs in biological fluids. Journal of Pharmaceutical Sciences and Technology, 2(10), 333-347.
33. Nicola C, Ernest Y, Fan J ,Bajaj N (2007), Determination of Carryover and Contamination for Mass Spectrometry–Based Chromatographic Assays; Journal of the American Association of Pharmaceutical Scientists, 9(3) Article 42.
34. Rajpoot B (2011), Validation and process development: A review. International. Research. Journal of Pharmacy, 2(1), 32-39.
35. Kole P (2011), Recent advances in sample preparation techniques for effective bioanalytical methods Biomedical Chromatography, Volume 25, Issue 1-2, 199–217.

36. Zhang J (2010), Rapid Communications in Mass Spectrometry, Volume 24, Issue 24, 3593–3601.
37. Kalakuntla R, Kumar K (2009), Bioanalytical method validation: A quality assurance auditor view point, J Pharm. Sci., Res.;1(3),1-10.
38. Wells D (2003), High throughput bioanalytical sample preparation: methods and automation strategies.
39. Sethi P (2001), High performance chromatography: quantitative analytical pharmaceutical formulations. 1st edition, Chapter 1 Introduction. Published by CBS publishers New Delhi, 3-40.
40. Health Canada, Guidance for industry-2012, Conduct and analysis of Bioavailability and Bioequivalence studies – Part A: Oral dosage formulations used for systemic effects, authority of the minister of health.